ABIONYX Pharma SA (EPA:ABNX)

France · Delayed Price · Currency is EUR

1.704

+0.062 (3.78%)

Nov 11, 2026, 5:35 PM CET

Market Cap	72.14M -50.8%
Revenue (ttm)	4.06M -10.7%
Net Income	-5.55M
EPS	-0.16
Shares Out	42.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	203,514
Open	1.668
Previous Close	1.642
Day's Range	1.620 - 1.734
52-Week Range	1.414 - 4.600
Beta	0.91
Analysts	Strong Buy
Price Target	9.75 (+472.18%)
Est. Earnings	Dec 24, 2026

About ABIONYX Pharma

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2005

Employees 49

Stock Exchange Euronext Paris

Ticker Symbol ABNX

Full Company Profile

Financial Performance

In 2025, ABIONYX Pharma's revenue was 4.06 million, a decrease of -10.72% compared to the previous year's 4.55 million. Losses were -5.55 million, 26.7% more than in 2024.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for ABNX stock is "Strong Buy." The 12-month stock price target is €9.75, which is an increase of 472.18% from the latest price.

Price Target

€9.75

(472.18% upside)

Analyst Consensus: Strong Buy

Stock Forecasts